Background: Serum thioredoxin-1 (TRX-1) may be a useful biomarker for early diagnosis of breast cancer. Subject and Methods: Thioredoxin -1 and cancer antigen15-3 levels were determined using Enzyme-Linked Immunosorbent Assay (ELISA) in 141 women: 55 had primary breast cancer, 35 with benign breast tumor and 51 were apparently healthy controls matched for age, waist circumference and body mass index. Diagnosis involved all women with breast mass who referred to the Histopathology Department, Duhok Specialized laboratory Center during the study period. Fine needle aspirate (FNA) cytology test was carried out first and then the findings were later on compared with histological results to confirm the diagnosis. Breast cancer women were further grouped into subtypes based on immunohistochemistry. The aim of this study was to assess the diagnostic capacity of thioredoxin-1 for primary breast cancer. Results: Significantly higher Thioredoxine -1 and cancer antigen15-3 levels (p=0.001 and p=0.011 respectively) were found in primary breast cancer group compared to benign breast tumor group and healthy women. In breast cancer group, positive test was observed 2 times more likely than in benign breast tumor group as well in healthy women, with a sensitivity of 94.5%, specificity 72.1% and Receiver Operating Characteristics Curve ROC 0.872. Totally different and less significant values were observed for cancer antigen15-3, sensitivity 16.4%, specificity 93.0% and Receiver Operating Characteristics Curve ROC 0.352. Conclusions: Elevated thioredoxin-1 level in conjunction with a high sensitivity and specificity may be strongly associated with primary breast cancer in women; this may indicate the needs for determining serum thioredoxin-1 as a screening test for early diagnosis of primary breast cancer Duhok Med J 2017; 11 (2): 19-26.
EVALUATION OF THIOREDOXIN-1 SERUM MARKER FOR EARLY DIAGNOSIS
survival in tumor patients and is used as independent prognostic factor for the progression and expression of vascular endothelial growth factor and redox factor-1 4 . Due to the early detection, it is important to search and assess such emerging biomarkers for breast cancer diagnosis. Therefore, the present study was carried out to assess the diagnostic capacity of TRX-1 for primary breast cancer. Table 1 shows the baseline characteristics of women with primary breast cancer, benign breast tumor and healthy controls. No significant differences were found with respect to age, WC and BMI between breast cancer groups and controls. Significantly higher CA15-3 and TRX-1 levels were observed in women with breast cancer group compared to controls (p=0.011 and p=0.001, respectively).
PATIENTS AND METHODS

RESULTS
A significant higher mean TRX-1 level (almost 2 times higher) was found in the breast cancer group compared with benign group (p=0.01). Parameters from ROC analysis on serum CA15-3 and TRX-1 levels between women with breast cancer and controls are presented in Table 2 and Figure 1 .
When the serum TRX-1 was measured in breast cancer women in comparison with healthy women, the area under curve To determine the usefulness of TRX-1 as a companion marker to CA15-3 as a screening test for primary breast cancer, we calculated its validity with regard to cut-off point of CA15-3 (35 U/ml).The diagnosis of breast cancer with the cut-off value of TRX-1(60.5 U/ml) was associated with a higher sensitivity (90.8%) compared to CA15-3 (9.2%), p=0.001 (Table 4) . The mean of serum TRX-1 and CA15-3 of Subtypes of breast cancer women are presented in Table 5 . No significant differences were observed with respect to immunohistochemistry results among the subgroups. 
DISCUSSION
The results of this study showed significantly higher TRX-1 levels in women with breast cancer compared with levels in healthy women as well as in women with benign breast tumor. The results confirm a higher sensitivity of TRX-1 than that of CA15-3, as the mean TRX-1 level observed in breast cancer women was 2 times higher than that observed in controls and women with benign breast tumor. These results are in accordance with previous studies 5, 6 .
Moreover, the current study reported nearly similar TRX-1 values in healthy women and benign group, suggesting that a different mechanism, other thanTRX-1 may involve benign tumorgenesis. The mechanism through which the TRX-1 play a role in the apoptosis has been suggested by many researchers 7 , oxidative stress, a characteristics feature of many cancers including the breast cancer, has been implicated in the cancer development and progression 8 . One of the most important cellular cytoplasmic redox system is the Thioredoxine system encompassed TRX-1, TRXR1 and NADPH 9 . It has a high expression in many cancer cells, including breast tumor 10 . TRX-1 can act as a direct scavenger of ROS, and reduced form inhibits apoptosis by binding to apoptosis signal regulating kinase -1(ASK-1) 11, 12 . An association between the high level of TRX-1 expression and aggressiveness of tumors in human cancer involving breast cancer has been also argued by others 13 .
However, none of the mentioned reports directly related any evidence of TRX-1 expression in benign breast tumor. It is interesting to note that when the serum TRX-1 was measured in breast cancer women in comparison with healthy women, the AUC (area under curve) value exceeded about 0.872, with the sensitivity and specificity detected more than 94% and 72% respectively. The global study by Park et, al. 3 also reported a high values of sensitivity 89.0%, specificity 78.0% and AUC 0,901. Our results suggest an important capacity for the early detection of breast cancer through TRX-1 measurements, although, the TRX-1 levels in the other relevant carcinomas has not been determined, which is a limitation of this study. This might underestimate the definitive conclusion regarding the role of TRX-1 specifically related to these patients with breast cancer. The drawback of the current study includes the lower sample size to evaluate the relationship between serum level of TRX-1 and tumor cells expression of estrogen receptor, progesterone receptor or Her2/ neu enriched. Therefore further studies considering these aspects may be necessary in the women with breast cancer.
Comparison of breast cancer with benign breast tumor and healthy controls women showed that the highest TRX-1 levels with its high sensitivity and specificity were detected in blood taken from breast cancer women. In addition we suggest that the capacity of TRX-1 for the early detection of breast cancer is higher than that of CA15-3, especially regarding sensitivity. The elevated thioredoxin-1 level in conjunction with a high sensitivity and specificity in women with breast cancer suggesting TRX-1 is strongly associated with primary breast cancer; this may indicate the needs for determining serum thioredoxin-1 as a screening test for early diagnosis of breast cancer.
